標靶癌症治療市場－全球產業規模、佔有率、趨勢、機會及預測，依治療類型、疾病適應症、最終用戶、地區及競爭情況細分，2020-2030 年預測

2024 年全球標靶癌症治療市場規模為 165.5 億美元，預計到 2030 年將達到 252.4 億美元，複合年成長率為 7.25%。該市場是更廣泛的腫瘤學領域的重要組成部分，強調針對導致癌症進展的特定基因突變、蛋白質或細胞環境的精準治療方法。標靶治療旨在最大限度地提高治療效果，同時最大限度地減少傳統化療和放療常見的附帶損害。本產業涵蓋單株抗體、激酶抑制劑、免疫檢查點抑制劑和小分子等一系列療法。持續的創新、研發投入和積極的臨床試驗管線正在加速產品開發，從而促進改善患者預後並擴大各種癌症類型的治療可能性。

關鍵市場促進因素

各類癌症發生率不斷上升

主要市場挑戰

標靶治療的高成本和副作用

主要市場趨勢

基因組分析與精準醫療的進展

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：癌症標靶治療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依治療類型（荷爾蒙療法、單株抗體、訊號傳導抑制劑、基因表現調節劑、凋亡抑制劑等）
  • 依疾病適應症（肺癌、乳癌、大腸癌、白血病、黑色素瘤、淋巴瘤、其他）
  • 按最終使用者（醫院和診所、癌症和放射治療中心、學術和研究機構）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美標靶癌症治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲標靶癌症治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太地區癌症標靶治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲標靶癌症治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲標靶癌症治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章：全球標靶癌症治療市場：SWOT 分析

第 14 章：競爭格局

• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Johnson & Johnson Service Inc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

The Global Targeted Cancer Therapy Market was valued at USD 16.55 Billion in 2024 and is projected to reach USD 25.24 Billion by 2030, growing at a CAGR of 7.25%. This market forms a crucial segment of the broader oncology landscape, emphasizing precision treatment approaches that act on specific genetic mutations, proteins, or cellular environments contributing to cancer progression. Targeted therapies aim to maximize treatment efficacy while minimizing collateral damage often seen with traditional chemotherapy and radiation. The industry includes an array of modalities such as monoclonal antibodies, kinase inhibitors, immune checkpoint inhibitors, and small molecules. Continued innovation, R&D investment, and active clinical trial pipelines are accelerating product development, thereby fostering improved patient outcomes and expanding therapeutic possibilities across various cancer types.

Key Market Drivers

Increasing Prevalence of Various Type of Cancers

Rising cancer prevalence globally is a major force fueling the demand for targeted cancer therapies. As of 2020, cancer accounted for nearly 10 million deaths annually, making it a dominant health and economic concern. Pediatric cancer remains a high-priority area, with roughly 400,000 new diagnoses each year. Patterns of incidence vary by geography, with cervical cancer topping the list in 23 countries, reflecting inequalities in HPV vaccination and screening. This variation signals untapped markets for tailored diagnostics and therapies. Lung cancer, representing about 12.4% of all new cancer cases, remains the deadliest, contributing to 18.7% of all cancer-related fatalities. As aging populations, lifestyle shifts, and environmental exposures drive global cancer rates upward, targeted therapies provide more effective, less toxic alternatives to conventional treatments. Their ability to deliver personalized, gene-specific interventions positions them as essential tools in modern oncology, especially in light of these growing epidemiological trends.

Key Market Challenges

High Cost and Side Effects Associated with the Targeted Therapies

The considerable cost of targeted cancer treatments presents a substantial hurdle to widespread adoption. Advanced therapies such as monoclonal antibodies and gene modulators demand high manufacturing investment and specialized administration, resulting in elevated prices for patients and healthcare systems. According to the American Association for Cancer Research, the U.S. could see national cancer-related costs exceed USD 245 billion by 2030-an increase of over 30% since 2015. Patients undergoing initial, ongoing, or end-of-life cancer care can incur average annual costs ranging from USD 5,300 to over USD 41,800. This economic burden affects access to care and can lead to financial distress for both patients and healthcare providers. Additionally, while targeted therapies are generally safer than traditional chemotherapy, they are not devoid of side effects, including immune-related adverse events or organ toxicity. These challenges call for innovative cost-control strategies, reimbursement policy revisions, and research into affordable alternatives to sustain market growth.

Key Market Trends

Advancements In Genomic Profiling and Precision Medicine

The integration of genomic profiling and precision medicine is transforming cancer treatment, driving greater adoption of targeted therapies. Next-generation sequencing (NGS) and liquid biopsy technologies now enable precise identification of genetic mutations that drive cancer, allowing clinicians to tailor treatment plans based on each patient's unique tumor profile. These innovations have led to more effective, personalized therapies with fewer adverse effects. Precision medicine is also becoming instrumental in tracking disease progression and resistance patterns, enabling real-time adjustments to treatment. As these tools become more accessible, healthcare systems worldwide are increasingly implementing genomic-based protocols. This evolution in oncology practice underscores the growing reliance on targeted treatments and supports their rising use as a mainstay in cancer care strategies.

Key Market Players

• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Johnson & Johnson Service Inc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.

Report Scope:

In this report, the Global Targeted Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Targeted Cancer Therapy Market, By Therapy Type:

• Hormone Therapies
• Monoclonal Antibodies
• Signal Transduction Inhibitors
• Gene Expression Modulators
• Apoptosis Inhibitors
• Others

Targeted Cancer Therapy Market, By Disease Indication:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Melanoma
• Lymphoma
• Others

Targeted Cancer Therapy Market, By End User:

• Hospitals & Clinics
• Cancer & Radiation Therapy Centers
• Academic & Research Institutions

Targeted Cancer Therapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Targeted Cancer Therapy Market.

Available Customizations:

Global Targeted Cancer Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Targeted Cancer Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (Hormone Therapies, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors, Others)
  • 5.2.2. By Disease Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, Lymphoma, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Cancer & Radiation Therapy Centers, Academic & Research Institutions)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Targeted Cancer Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Disease Indication
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Targeted Cancer Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Disease Indication
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Targeted Cancer Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Disease Indication
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Targeted Cancer Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Disease Indication
      • 6.3.3.2.3. By End User

7. Europe Targeted Cancer Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By Disease Indication
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Targeted Cancer Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Targeted Cancer Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Targeted Cancer Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By End User
  • 7.3.4. France Targeted Cancer Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Disease Indication
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Targeted Cancer Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Disease Indication
      • 7.3.5.2.3. By End User

8. Asia-Pacific Targeted Cancer Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Disease Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Targeted Cancer Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. India Targeted Cancer Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Targeted Cancer Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Targeted Cancer Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By Disease Indication
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Targeted Cancer Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By Disease Indication
      • 8.3.5.2.3. By End User

9. South America Targeted Cancer Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Disease Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Targeted Cancer Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Targeted Cancer Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Targeted Cancer Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By End User

10. Middle East and Africa Targeted Cancer Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type
  • 10.2.2. By Disease Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Targeted Cancer Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By Disease Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Targeted Cancer Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By Disease Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Targeted Cancer Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By Disease Indication
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Targeted Cancer Therapy Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Amgen Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. AstraZeneca plc
• 14.3. Bayer AG
• 14.4. Bristol-Myers Squibb Company
• 14.5. F. Hoffmann-La Roche Ltd
• 14.6. GlaxoSmithKline plc
• 14.7. Johnson & Johnson Service Inc.
• 14.8. Merck & Co. Inc.
• 14.9. Novartis AG
• 14.10.Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer